Patch eliminates colorectal cancer

Researchers at MIT are developing 

an adhesive patch that can stick to 

a tumor site, either before or after 

surgery. – Image courtesy IMES

CANCER DIGEST – Aug. 6, 2016 – One day your doctor may use a patch, much like nicotine patches used to help people stop smoking, to eradicate colon cancer and keep it from coming back, according to a report in the journal Nature Materials.

In an experiment done in mice, researchers at MIT’s Institute for Medical Engineering and Science, have shown that the patch, designed to deliver a triple combination of therapies, was effective whether the tumor was completely removed or not. By contrast, 40 percent of the mice with no patch applied after tumor removal, saw tumor recurrence.

Blocking glutamine may starve colorectal cancer cells

A molecular model of L-glutamine. Image courtesy Jynto
via Wikimedia Commons

CANCER DIGEST – July 31, 2016 – A new clinical trial set to get under way later this summer will try to determine if denying certain types of colorectal cancer cells a specific nutrient will starve them to death.

The Case Western Reserve University trial is based on laboratory and mouse studies showing that colorectal cancer cells with a genetic mutation called PIK3CA died when deprived of the nutrient glutamine, which is an amino acid used by cells to make proteins. This mutation is located in a gene critical for cell division and movement, and is found in approximately one third of all colorectal cancers. Glutamine is the most abundant free amino acid in human blood and is mostly made in muscle tissue.

Skin cancer screenings don’t boost referrals or surgeries

Melanoma can be cured if caught early. Image courtesy
Brown University

CANCER DIGEST – July 20, 2016 – A new study of more than 1,000 primary care melanoma screenings in the western Pennsylvania area suggests that such screenings would not be harmful as some experts had thought.

Melanoma is one of those cancers that can be cured if caught early, which has led to some experts calling for widespread training of primary care providers to conduct screenings at routine visits. Other experts, however, have worried that widespread screening could lead to overtreatment and unnecessary patient distress.

Education key to acceptance of surgery step to prevent ovarian cancer

CANCER DIGEST – July 12, 2016 – Ovarian cancer most often starts in the fallopian tubes, an observation that caused the American College of Obstetricians and Gynecologists (ACOG) to issue an opinion in January 2015 recommending that women undergoing hysterectomies for non-cancerous conditions should also have the fallopian tubes removed, while sparing the ovaries as a way to prevent ovarian cancer.

In issuing their opinion, the ACOG acknowledged that randomized controlled clinical trials are needed to determine if salpingectomy, or removing fallopian tubes, does reduce ovarian cancer risk.

Gene complex predicts ovarian cancer survival

Richard Morgan is the Director of the University of 

Bradford's Institute of Cancer Therapeutics in the UK

Image courtesy of U of Bradford

CANCER DIGEST  – June 29, 2016 – A new British study has identified a genetic marker that predicts poor survival from ovarian cancer. In addition, the study also identified a set of genes that help the cancer develop resistance to chemotherapy.

The study, published in the International Journal of Cancer, examined the role of HOX genes in ovarian cancer resistance to chemotherapy and whether a drug known as HXR9, which targets HOX, could help prevent the resistance from developing.